Comparing treatment timing in recurrent nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial compares giving chemotherapy and immunotherapy before surgery (neoadjuvant) versus after surgery (adjuvant) for patients whose nasopharyngeal cancer has returned locally. It aims to find which approach works better to control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer that has come back after completing your first radiation treatment.
- The tumor is removable with surgery and is at a certain stage (T2 deep, T3 not in sphenoid sinus only, or T4).
- You are between 18 and 75 years old.
- Your general health is good enough to undergo surgery, chemotherapy, and immunotherapy (ECOG score 0-2).
- You do not have other serious medical conditions or active autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether adding chemo-immunotherapy after surgery is better than surgery alone for patients whose nasopharyngeal cancer has returned but is still in early stages. It may help prevent the cancer from coming back again.
This study compares two treatments—surgery or IMRT (a targeted type of radiation)—for early-stage cancer that has come back in the nasopharynx without spreading. It aims to see which approach works better and is safest for people in your situation.
This trial studies toripalimab (an immunotherapy that helps your immune system attack cancer) for nasopharyngeal cancer that has come back locally. It may help shrink or control the returning tumor and improve outcomes for people who meet the safety and lab requirements.
This trial tests giving chemotherapy before and after surgery for people whose nasal cancer has come back. The goal is to see if this approach helps remove the cancer more effectively and prevents it from returning again.
This trial is testing the best timing for adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy for people with advanced nasopharyngeal cancer that has not spread. It aims to improve treatment effectiveness.
This phase 3 trial tests whether adding toripalimab (an immunotherapy medicine) to standard chemo-radiation works better for treating nasopharyngeal cancer that has come back and cannot be removed by surgery. It aims to improve control of the cancer after it returns.
Hear when a new Recurrent Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.